Traders should monitor the outcome of Moderna's appeal to the Federal Circuit, as a negative ruling could trigger a $1.3 billion payment. The settlement removes long-term royalty uncertainty for Moderna's vaccine pipeline but creates near-term cash flow pressure.
Price Chart
Executive Summary
Moderna entered into a settlement agreement with Arbutus Biopharma and Genevant Sciences to resolve all ongoing patent infringement litigation related to its vaccines, including Spikevax and mRESVIA. Moderna will make a $950 million noncontingent payment by July 8, 2026, and may face an additional $1.3 billion contingent payment depending on the outcome of its appeal regarding U.S. government contract protections under 28 U.S.C. 1498.
Key Financial Metrics
Key Facts
- Moderna agreed to pay $950 million noncontingent lump sum to Arbutus/Genevant by July 8, 2026.
- An additional contingent payment of up to $1.3 billion may be required if Moderna loses its appeal on 28 U.S.C. 1498 defense.
- The settlement resolves all worldwide litigation related to Spikevax, mRESVIA, and provides certainty for Moderna's infectious disease portfolio with no future royalties.
- If the Federal Circuit rules that 1498 bars infringement claims for some vaccine doses, the contingent payment will be prorated.
- Arbutus/Genevant must return the contingent payment plus interest if a final decision later favors Moderna.
Financial Impact
Immediate cash outflow of $950 million and potential additional liability of up to $1.3 billion, representing approximately 5.7% of Moderna's $22.8B market cap if fully paid.
Risk Factors
- Contingent $1.3 billion payment obligation if Moderna loses its 1498 appeal
- Potential cash flow strain from large near-term payment
- Market perception of admitting infringement liability despite appeal
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001682852-26-000047 |
| Document: 0001682852-26-000047-index-headers.html | 0001682852-26-000047 |
| Document: 0001682852-26-000047-index.html | 0001682852-26-000047 |
| Document: 0001682852-26-000047.txt | 0001682852-26-000047 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 2d ago | ANALYST-DOWNGRADE | — | awaiting T+5 | — | — |
Sep 3, 2026 29d ago | ANALYST-DOWNGRADE | $148.87 $143.97 | ▲ +3.29% | ▲ +2.14% | $187.38 (−25.87%) |
Aug 31, 2026 4w ago | Court Ruling | $140.19 $140.33 | ▼ −0.10% | ▼ −0.24% | $187.38 (−33.66%) |
Aug 25, 2026 5w ago | ANALYST-UPGRADE | $158.83 $154.27 | ▼ −2.87% | ▼ −2.33% | $187.38 (+17.98%) |
Aug 19, 2026 6w ago | ANALYST-UPGRADE | $174.38 $149.66 | ▼ −14.18% | ▼ −13.79% | $187.38 (+7.45%) |
Aug 5, 2026 8w ago | 144 | $56.26 $63.67 | ▼ −13.18% | ▼ −12.83% | $187.38 (−233.09%) |
Jul 31, 2026 9w ago | 8-K | $54.82 $59.17 | ▲ +7.94% | ▲ +4.42% | $187.38 (+241.81%) |
Jul 10, 2026 11w ago | 3 | $67.01 $61.82 | ▼ −7.75% | ▼ −6.96% | $187.38 (+179.63%) |
Jul 8, 2026 12w ago | 8-K | $73.80 $67.44 | ▼ −8.62% | ▼ −9.48% | $187.38 (+153.90%) |
Jun 18, 2026 15w ago | 144 | $63.96 $59.75 | ▼ −6.58% | ▼ −4.92% | $187.38 (+192.96%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access